Intradermal hepatitis B vaccination in patients with advanced chronic renal failure: Immunogenicity and follow-up

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 7, 2007, Pages 849-855

  Morais, E O ^b,c   Resende, M R ^b,c   Oliveira, A M ^d   Sinkoc, V M ^c   Garcia, M T ^c   Angerami, R N ^b,c   Da Silva, L J ^a,b,c  

^a Unicamp ^*  (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; APPLICATION SITE HYPERPIGMENTATION; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; COURSE EVALUATION; DRUG EFFECT; DRUG INDUCED HEADACHE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION;

EID: 33947279040     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03210.x     Document Type: Article

References (35)

1. Tang S, Lai KN. Chronic viral hepatitis in hemodialysis patients. Hemodial Int 2005; 9: 169-79.
2. CDC. Recommendations of the immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR 1982; 31: 317-22.
3. CDC. Recommendations for preventing transmission of infections among chronic haemodialysis patients. MMWR 2001; 50: 1-43.
4. Peces R, de la Torre M, Alcazar R, Urra M. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in haemodialysis patients. Am J Kidney Dis 1997; 29(2): 239-45.
5. Pesanti EL. Immunologic defects and vaccination in patients with chronic renal failure. Inf Dis Clin N America 2001; 15: 813-32.
6. Docci D, Cipolloni PA, Mengozzi S, Baldrati L, Capponcini C, Feletti C. Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients: a two-year follow-up. Nephron 1992; 61: 352-4.
7. Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 1996; 73: 417-20.
8. Brodersen HP, Holtkamp W, Larbig D, et al. Zinc supplementation and hepatitis B vaccination in chronic haemodialysis patients: a multicentre study. Nephrol Dial Transplant 1995; 10: 1780(Letter).
9. Quiroga JA, Castillo I, Porres JC, et al. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in haemodialysis patients. Hepatology 1990; 12: 661-3.
10. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994; 244: 856-7.
11. Anandh U, Bastani B, Ballal S. Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance haemodialysis patients. Am J Nephrol 2000; 20: 53-6.
12. Jha R, Lakhtakia S, Jaleel MA, Narayan G, Hemlatha K. Granulocyte macrophage colony stimulating factor (GM-CSF) induced sero-protection in end stage renal failure patients to hepatitis B in vaccine non-responders. Ren Fail 2001; 23: 629-36.
13. Singh NP, Mandal SK, Thakur A, et al. Efficacy of GM-CSF as an adjuvant to hepatitis B vaccination in patients with chronic renal failure - results of a prospective, randomised trial. Ren Fail 2003; 5: 255-66.
14. Verkade MA, van de Wetering J, Klepper M, Vaessen LM, Weimar W, Betjes MG. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in haemodialysis patients. Kidney Int 2004; 66: 614-21.
15. Anandh U, Thomas PP, Shastry JC, Jacob CK. A randomised controlled trial of intradermal hepatitis B vaccination and augmentation of response with erythropoietin. J Assoc Physicians India 2000; 48: 1061-3.
16. Weinstein T, Chagnac A, Boaz M, et al. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin Pract 2004; 97: 67-72.
17. Tong NK, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvant hepatitis B vaccine in pre-haemodialysis and haemodialysis patients. Kidney Int 2005; 68: 2298-303.
18. Zuckerman AJ. Appraisal of intradermal immunization against hepatitis B. Lancet 1987; 1: 435-6.
19. Propst T, Propst A, Lhotta K, Vogel W, Konig P. Reinforced intradermal hepatitis B vaccination in haemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32: 1041-5.
20. Vlassopoulos D, Arvanitis D, Lilis D, Hatjiyannakos D, Louizou K, Hadjiconstantinou V. Complete success of intradermal vaccination against hepatitis b in advanced chronic renal failure and haemodialysis patients. Ren Fail 1997; 19: 55-60.
21. Milkowski A, Wyrwicz G, Kubit P, Smolenski O. Comparison of anti-HBV vaccine efficacy given intradermally and intramuscularly in haemodialysis patients. Przegl Lek 2000; 57: 628-34.
22. National Kidney Foundation. K ? DOQI clinical practice guidelines fro chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 2(Suppl. 1): S1-266.
23. Ono K, Kashiwagi S. Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients. Nephron 1991; 58: 47-51.
24. Waite NM, Thomson LG, Goldstein MB. Successful Vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol 1995; 5: 1930-4.
25. Chang PC, Schrander-van der Meer AM, Van Dorp WT, Van Leer E. Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrol Dial Transplant 1996; 11: 191-3.
26. Bruguera M, Rodicio JL, Alcazar JM, Oliver A, Del Rio G, Esteban-Mur R. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990; 8(Suppl.): S47-9.
27. Mettang T, Schenk U, Thomas S, et al. Low dose intradermal versus intramuscular hepatitis B vaccination in patients with end stage renal failure. Nephron 1996; 72: 192-6.
28. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12: 1204-11.
29. Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 976-82.
30. Fabrizi F, Ganeshan SV, Dixit V, Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther 2006; 24: 497-506.
31. Chutivongse S, Wilde H, Supich C, Baer GM, Fishbein DB. Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 1990; 335: 896-8.
32. Phanuphak P, Khawplod P, Sirivichayakul S, Siriprasomsub W, Ubol S, Thaweepathomwat M. Humoral and cell-mediated immune responses to various economical regimens of purified Vero cell rabies vaccine. Asian Pac J Allergy Immunol 1987; 5: 33-7.
33. Glenn GM, Kenney RT. Mass vaccination: solutions in the skin. Curr Top Microbiol Immunol 2006; 304: 247-68.
34. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 2004; 20: 1053-62.
35. Mat O, Mestrez F, Beauwns R, Muniz-Martinez MC, Dhaene M. Primary high-dose intradermal hepatitis B vaccination in hemodialysis: cost-effectiveness evaluation at 2 years. Hemodial Int 2006; 10: 49-55.